Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
42,602
result(s) for
"Research Letters"
Sort by:
Evaluating the performance of large language models: ChatGPT and Google Bard in generating differential diagnoses in clinicopathological conferences of neurodegenerative disorders
by
Martin, Nicholas B.
,
Koga, Shunsuke
,
Dickson, Dennis W.
in
Alzheimer's disease
,
Amyotrophic lateral sclerosis
,
Artificial Intelligence
2024
This study explores the utility of the large language models (LLMs), specifically ChatGPT and Google Bard, in predicting neuropathologic diagnoses from clinical summaries. A total of 25 cases of neurodegenerative disorders presented at Mayo Clinic brain bank Clinico‐Pathological Conferences were analyzed. The LLMs provided multiple pathologic diagnoses and their rationales, which were compared with the final clinical diagnoses made by physicians. ChatGPT‐3.5, ChatGPT‐4, and Google Bard correctly made primary diagnoses in 32%, 52%, and 40% of cases, respectively, while correct diagnoses were included in 76%, 84%, and 76% of cases, respectively. These findings highlight the potential of artificial intelligence tools like ChatGPT in neuropathology, suggesting they may facilitate more comprehensive discussions in clinicopathological conferences. This study assessed the capability of large language models, namely ChatGPT and Google Bard, in predicting neuropathologic diagnoses from 25 cases presented at Mayo Clinic brain bank clinicopathological conferences. ChatGPT‐4 rendered correct diagnoses in 84% of cases, whereas ChatGPT‐3.5 and Google Bard each achieved 76%. These findings highlight the potential of large language models in neuropathology, suggesting they may facilitate more comprehensive discussions in clinicopathological conferences.
Journal Article
Real-World Experience of Using Dupilumab and Jak Inhibitors to Manage Pruritus in Epidermolysis Bullosa Pruriginosa
by
Hou, Ping-Chen
,
Tu, Wei-Ting
,
McGrath, John A.
in
Conflicts of interest
,
Inflammation
,
Kinases
2024
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
Graphical Abstract
Graphical Abstract
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
Journal Article
Electrostatic gating of hybrid halide perovskite field-effect transistors: balanced ambipolar transport at room-temperature
by
Zhang, C.
,
Jurchescu, O.D.
,
Vardeny, Z.V.
in
Biomaterials
,
Characterization and Evaluation of Materials
,
Materials Engineering
2015
The hybrid halide perovskites combine the low-cost processing characteristics of organic materials with the performance factors of inorganic compounds. Recently the power conversion efficiencies of perovskite photovoltaic solar cells have reached a respective value of ~20%. The charge transport properties were indirectly approximated in these compounds because of lack of available field-effect transistors (FETs). Here we report the fabrication and room-temperature operation of FETs based on the hybrid perovskites. We obtained balanced electron and hole transport with mobilities of ~1 cm2/Vs. We also found that the yield, as well as the operational and environmental stability of the fabricated transistors is limited.
Journal Article
Eczematous Eruption During Bimekizumab Treatment in a Psoriatic Patient Previously Treated with Secukinumab
by
Falco, Gennaro Marco
,
D’Amore, Alessandra
,
Simone, Clara
in
Cytokines
,
Eczema
,
Histopathology
2024
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
Graphical Abstract
Graphical Abstract
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
Journal Article